StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Evolus total assets

Total assets on the balance sheet at the end of each period.

Evolus's total assets was $248.02M at Jun 30, 2026. For fiscal 2025 it was $225.87M, down 2.9% from the year before. The highest annual figure on record is $257.48M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$225.87M-2.9%
FY2024Dec 31, 2024$232.57M+23.1%
FY2023Dec 31, 2023$189.00M+6.2%
FY2022Dec 31, 2022$177.98M-30.9%
FY2021Dec 31, 2021$257.48M+23.2%
FY2020Dec 31, 2020$209.07M-13.0%
FY2019Dec 31, 2019$240.44M+39.9%
FY2018Dec 31, 2018$171.84M+12.9%
FY2017Dec 31, 2017$152.23M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$248.02M+8.4%
Q1 FY2026Mar 31, 2026$220.65M+3.4%
Q4 FY2025Dec 31, 2025$225.87M-2.9%
Q3 FY2025Sep 30, 2025$219.00M-4.6%
Q2 FY2025Jun 30, 2025$228.80M-2.1%
Q1 FY2025Mar 31, 2025$213.36M-5.7%
Q4 FY2024Dec 31, 2024$232.57M+23.1%
Q3 FY2024Sep 30, 2024$229.61M+36.7%
Q2 FY2024Jun 30, 2024$233.77M+38.3%
Q1 FY2024Mar 31, 2024$226.18M+41.2%
Q4 FY2023Dec 31, 2023$189.00M+6.2%
Q3 FY2023Sep 30, 2023$167.97M-12.8%
Q2 FY2023Jun 30, 2023$168.98M-19.9%
Q1 FY2023Mar 31, 2023$160.24M-27.4%
Q4 FY2022Dec 31, 2022$177.98M-30.9%
Q3 FY2022Sep 30, 2022$192.72M-10.5%
Q2 FY2022Jun 30, 2022$210.92M-12.1%
Q1 FY2022Mar 31, 2022$220.66M+40.4%
Q4 FY2021Dec 31, 2021$257.48M+23.2%
Q3 FY2021Sep 30, 2021$215.22M-0.3%
Q2 FY2021Jun 30, 2021$239.86M+23.3%
Q1 FY2021Mar 31, 2021$157.20M-26.6%
Q4 FY2020Dec 31, 2020$209.07M-13.0%
Q3 FY2020Sep 30, 2020$215.78M+18.1%
Q2 FY2020Jun 30, 2020$194.54M-4.1%
Q1 FY2020Mar 31, 2020$214.15M-3.1%
Q4 FY2019Dec 31, 2019$240.44M+39.9%
Q3 FY2019Sep 30, 2019$182.67M-0.4%
Q2 FY2019Jun 30, 2019$202.78M+66.3%
Q1 FY2019Mar 31, 2019$220.93M+73.4%
Q4 FY2018Dec 31, 2018$171.84M+12.9%
Q3 FY2018Sep 30, 2018$183.38M–
Q2 FY2018Jun 30, 2018$121.93M–
Q1 FY2018Mar 31, 2018$127.40M–
Q4 FY2017Dec 31, 2017$152.23M–

More Evolus figures

See a number that looks wrong?